anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open label pilot study. Thirty patients with ESRD who qualify for emergent dialysis on the basis of serum potassium greater than 6mEq/L will be randomly assigned, using a random number generator in blocks of sixes, to standard-of-care (standard care) or patiromer group. Patients in the patiromer group will be given a single dose of 25.2g of patiromer in addition to standard-of-care treatment after randomization. Standard-of-care is defined as intervention or care provided by clinical provider according to individual practice pattern or hospital protocol. Each group of 15 patients will be observed with telemetry monitoring for 10 hours or till hemodialysis units become available for treatment (whichever comes first). Blood draws and electrocardiograms (ECGs) will be performed at enrollment and at 1, 2, 4, 6, 8 and 10hrs thereafter. Serum will be analyzed for basic metabolic panel and magnesium. Medications, including potassium lowering agents, administered during this period will be documented.

1. Informed consent will be obtained. 2. Subject will be randomized. 3. A. Randomized to Standard of Care (SOC): data will be collected on SOC treatment. 3. B. Randomized to patiromer group: subjects will receive a single dose of 25.2g of patiromer. SOC data will be collected. 4. all subjects will have blood drawn and ECGs (1 12 lead ECG and 1 Lead I Rhythm strip) done at baseline, 1, 2, 4, 6, 8 and 10 hours. Blood will be analyzed for basic metabolic panel and magnesium. 5. CRF completion-SOC data will be recorded in addition to current medications. 6. After subjects have received hemodialysis or reach the 10 hour study period, whichever comes first, the subject will be completed on the study.
The invention discloses 'a whitening skin cream and a process for preparation', which relates to the cosmetic field. The whitening skin cream mainly contains jalapin seeds oil, stearic acid, acetylated lanolin, glycerin, stearyl alcohol, methylis oxybenzoas and triethanolamine. The weight ratio of the jalapin seeds oil and glycerin is 1:1. The invention resolves the problem that the jalapin seeds oil is easy to perspire by unique proportioning and processing technology. The invention can be used in long term as cosmetic, has no imperfect side effect and stimulation on the skin of face and other potions of body, has significant therapeutic effect on comedo, ringworm, verruca, and acne, and has the efficacy of relieve itching and sterilizing. The invention is a cosmetic, curative, functional and natural skin care product.
PURPOSE: To obtain the subject compound useful for treating ovarian, mammary, pulmonary cancers, etc., with good productivity by culturing a tissue, a cell, etc., of a plant capable of producing a taxane type diterpene in a culture medium containing a saccharide and nitrate ions at specific concentrations under specified conditions and recovering the resultant product. CONSTITUTION: A tissue or a cell or both of a plant capable of producing a taxane type diterpene (e.g. Taxus breviflolia) are transplanted into a culture medium containing a sucrose, glucose or fructose at 2-50g/l concentration thereof, nitrate ions such as potassium nitrate, sodium nitrate or calcium nitrate at 2-50mmol/l concentration thereof in culturing the tissue or the cell or both of plant capable of producing the taxane type diterpene. A nutrient source solution daily containing the saccharide at 0.2-5g/l concentration or the nitrate ions at 0.2-5mmol/l concentration based on the initial volume of the culture medium or both is continuously or intermittently added to the culture medium to carry out the culture.  The resultant product is recovered from the prepared cultured product to thereby afford the objective taxane type diterpene (e.g. taxol) useful as a therapeutic agent for ovarian, mammary, pulmonary cancers, etc.
The invention relates to biotechnology, to gene therapy DNA vectors, a  Escherichia coli  strain JM110-NAS, a method of its production and selection of gene therapy DNA vector for targeted gene therapy. The method of a gene therapy DNA vector for targeted gene therapy includes construction of a 2408 bp vector containing a 688 bp replication origin, a 467 bp transcription terminator hGH-TA, a 137 bp regulatory region RNA-out of transposon TnlO, a 1018 bp kanamycin resistance gene, and a 68 bp poly linker. Vector cleaving by XhoI and BamHI restriction endonucleases and ligation with promoter and regulatory region, while a site containing the promoter region of a human is used for the production of the gene therapy DNA vector of interest. The kanamycin resistance gene is cleaved by SpeI restriction sites. The remaining fragment was ligated to itself. The invention allows high effective targeted gene therapy.
The invention relates to urination promoting and dampness dispelling health preservation powder. According to the adopted formula, the health preservation powder is prepared from, by weight, 20-30 parts of black beans, 35-45 parts of brown rice, 10-15 parts of red dates and 6-8 parts of traditional Chinese medicine powder. As for the adopted formula of the traditional Chinese medicine powder, the traditional Chinese medicine powder is prepared from, by weight, 2-4 parts of salvia miltiorrhiza, 4-8 parts of oriental wormwood, 1-4 parts of ganoderan and 3-6 parts of rhizoma atractylodis macrocephalae. The urination promoting and dampness dispelling health preservation powder has the beneficial effects that the solubleness is good, the taste is delicate, the nutrition is rich, and the powder is convenient to take. In addition, the powder is obtained through combination of traditional Chinese medicine, the synergistic interaction effect is remarkable, and through combination of the components, the functions of remarkably improving the immunity of the organism, promoting urination, dispelling dampness, clearing heat, expelling toxins, tonifying the spleen and gallbladder, nourishing the heart, tranquilizing mind and the like are achieved. The urination promoting and dampness dispelling health preservation powder is safe, effective and free of toxic and side effects.
OBJECTIVE: An ethmoid-dominant shadow on computed tomography is an indicator of type 2 inflammation, and is one of the main items used to diagnose and classify the severity of eosinophilic chronic rhinosinusitis in the Japanese diagnostic criteria. Ethmoid sinus dominance is examined using the Lund-Mackay scoring system and may be overestimated due to scoring characteristics. We aim to investigate the accuracy of evaluations of ethmoid dominance using the conventional scoring system and the possibility of conducting an objective evaluation using a more detailed other scoring system.
METHODS: Patients diagnosed with eosinophilic chronic rhinosinusitis and who underwent bilateral endoscopic sinus surgery were enrolled in the present study. Computed tomography was performed preoperatively on all subjects. The bilateral anterior and posterior ethmoid sinuses and bilateral maxillary sinus were scored, and the ethmoid-to-maxillary ratio was calculated using 3 different scoring systems: Lund-Mackay (each sinus score ranges between 0 and 2), simplified Zinreich (score ranging between 0 and 3), and Zinreich (score ranging between 0 and 5).
RESULTS: A total of 149 patients were eligible for the present study. Significant differences were observed in ethmoid-to-maxillary ratio evaluated by the 3 different scoring systems (2.4 ± 0.7, 3.0 ± 1.1, and 3.7 ± 2.2). Only 2 patients were negative for ethmoid dominance by the Lund-Mackay scoring system, while 14 were negative by the simplified-Zinreich and Zinreich scoring systems. Severity changed from the initial grade in 12 patients.
CONCLUSIONS: The present results confirmed a potential overestimation when only the Lund-Mackay scoring system was used to assess ethmoid dominance. Ethmoid dominance has been identified as one of the main predictive factors for the long-term postoperative outcomes of eosinophilic chronic rhinosinusitis and is included in the Japanese diagnostic criteria. A detailed evaluation of ethmoid dominance is desirable for more accurate evaluations of the severity and prognosis of eosinophilic chronic rhinosinusitis.
TH-302 is designed to target the hypoxic regions of tumors which are generally located distant from tumor vessels. Doxorubicin has poor tissue penetration and targets the regions of tumors that are located in proximity to the tumor vessels. The presence of hypoxia in solid tumors is associated with a more malignant phenotype and resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to selectively target the hypoxic microenvironment. Soft tissue sarcomas have evidence supporting the presence of hypoxia based on pO2 histography, F-MISO and gene expression profiling. There is an absence of therapeutic options for subjects with soft tissue sarcoma. Combining doxorubicin with TH-302 may enable the targeting of both the normoxic and hypoxic regions of soft tissue sarcoma.
Provided is a complex having growth differectiation factor 15 (GDF15) activity comprising a first heterodimer and a second heterodimer, each of them comprising: (i) a first polypeptide comprising from N-terminus to C-terminus a human IgG Fc sequence comprising a hinge region and a CH3 sequence comprising at least one engineered protuberance comprising at least one substitution of the corresponding amino acid in a human IgG1 Fc sequence, wherein the substitution is selected from the group consisting of Q347W/Y, T366W/Y and T394W/Y according to EU numbering; and (ii) a second polypeptide comprising from N-terminus to C-terminus a human IgG Fc sequence comprising a hinge region and a CH3 sequence comprising at least one engineered cavity comprising at least one substitution of the corresponding amino acid in a human IgG1 Fc sequence, wherein the substitution is selected from the group consisting of T366S, L368A, T394S, F405T/V/A, and Y407T/V/A according to EU numbering. The first polypeptide dimerizes with the second polypeptide via positioning of the protuberance of the first polypeptide into the cavity of the second polypeptide. Either the C-terminus of the first polypeptide or the C-terminus of the second polypeptide is conjugated to the N-terminus of a GDF15 mutein via a linker, wherein the GDF15 mutein comprises a contiguous amino acid sequence at least 98 amino acids long and at least 95% identical to the amino acid sequence of SEQ ID NO: 1, wherein the C-terminal amino acid of the GDF15 mutein corresponds to isoleucine at position 112 in SEQ ID NO: 1, and this contiguous amino acid sequence does not include the first two amino present at the N-terminus of SEQ ID NO: 1. The GDF15 mutein includes the substitution D5T relative to the amino acid sequence SEQ ID NO: 1. Also, the GDF15 mutein in the first heterodimer dimerizes with the GDF15 mutein in the second heterodimer thereby forming the complex comprising the first heterodimer and the second heterodimer. Also provided are a pharmaceutical composition comprising said complex, methods of treating obesity and treating or preventing hyperglycemia by administering said complex, nucleic acids encoding said first polypeptide or said second polypeptide, expression vectors comprising such nucleic acids, a host cell comprising such nucleic acids or such vectors.
OBJECTIVE: To acknowledge that minimally invasive pelvic exenteration is a feasible alternative to open surgery and potentially identify prediction factors for patient outcome.
METHODS: The study was designed as a retrospective single team analysis of 12 consecutive cases, set between January 2008 and January 2022.
RESULTS: Six anterior and 6 total pelvic exenterations were performed. A 75% of cases were treated using a robotic approach. In 4 cases, an ileal conduit was used for urinary reconstruction. Mean operative time was 360±30.7 minutes. for anterior pelvic exenterations and 440±40.7 minutes. for total pelvic exenterations and mean blood loss was 350±35 mL. An R0 resection was performed in 9 cases (75%) and peri-operative morbidity was 16.6%, with no deaths recorded. Median disease-free survival was 12 months (10-14) and overall survival (OS) was 20 months (1-127). In terms of OS, 50% of patients were still alive 24 months after surgery. Taking into consideration the follow up period,16.6% of females under 50 or above 70 years old did not reach the cut off and 4 out of 6 patients that failed to reach it were diagnosed with distant metastases or local recurrence (p=0.169).
CONCLUSION: Our experience is very much consistent with literature in regard to primary site of cancer, post-operative complications, R0 resection and survival rates. On the other hand, minimally invasive approach and urinary reconstruction type were in contrast with cited publications. Minimally invasive pelvic exenteration is indeed a safe and feasible procedure, providing patients selection is appropriately performed.
PURPOSE:A dental cement having proper thermal conductivity, high hardness and durability, capable of improving properties of tooth, obtained by blending an inorganic cement with any compound of an oxide, carbide, and nitride in such way that the cement has proper thermal conductivity and hardness. CONSTITUTION:A resin cement such as carboxylate resin, polyester resin, etc. or an inorganic cement such as zinc phosphate, calcium hydroxide, etc. is blended with one or more selected from any oxide, carbide, nitride and its mixture in order to make thermal conductivity and hardness reach properly given values. For example, when 10wt% ZrO2 or Y2O3 is added to zine phosphate cement, thermal conductivity is reduced to about 1/2, and hardness is raised by 30%. When the cement has low thermal conductivity, power to stimulate dental nerve of dental pulp caused by temperature transfer of food and drink is weak, heat to be transferred to the fresh in the vicinity of tooth is low, so the cement can correspond well to change in temperature range of food and drink, and provide preferably wide tasty feeling.
The present invention relates to an application of fenugreek total alkali extract in the process of preparing a medicine for treating ulcerative colitis and a preparation method of a colon targeting preparation. The present invention discloses an application of fenugreek total alkali extract in the process of preparing a medicine for treating ulcerative colitis, particularly an application of a colon targeting preparation. The present invention has an effective position using a single Chinese medicine, and is favorable to product stability and quality control. A targeting preparation is released in a colon, and the absorption of an upper gastrointestinal tract is reduced. The targeting preparation is directly released in a diseased region, and can be dispersed in the whole colon at high concentration, and the diseases are effectively and definitely treated. The targeting preparation reduces the stimulation of the medicine for the upper gastrointestinal tract, and the adverse effect is little. The present invention has the advantages of convenient use, good compliance, easy acceptance by patients, etc.
Discoidin domain receptors (DDR) play crucial roles in cell proliferation and differentiation. When DDRs are overexpressed, it has been associated with various diseases such as cancers, fibrotic disorders, and inflammation. This study aimed to expand on previous research by using a structure-based drug design approach to develop a series of new indole-urea derivatives as potent inhibitors of DDR1. Through biochemical analyses, it was found that these compounds effectively inhibited DDR1/2, with compound 7s demonstrating the highest activity against A549 cells (IC50 value of 1.84 μM) while maintaining selectivity for other kinases. In vivo studies showed that compound 7s exhibited stronger antitumor activity compared to dasatinib, without causing significant weight loss at a dose of 30 mg/kg. Further investigation revealed that compound 7s hindered the migration of A549 cells by targeting the ERK, Akt1, and EMT pathways. Additionally, cellular experiments demonstrated that compound 7s suppressed the activation of fibroblasts induced by TGF-β1. In vivo experiments confirmed that compound 7s, at a dose of 30 mg/kg, effectively inhibited DDR1 activation, resulting in a reduction of lung injury and fibrosis induced by bleomycin. Overall, these findings highlight the potential of these novel DDR1 inhibitors as promising therapeutic candidates for the treatment of DDR-related diseases.
Chronic kidney disease (CKD) poses a significant global health dilemma, emerging from complex causes. Although our prior research has indicated that a deficiency in Reticulon-3 (RTN3) accelerates renal disease progression, a thorough examination of RTN3 on kidney function and pathology remains underexplored. To address this critical need, we generated Rtn3-null mice to study the consequences of RTN3 protein deficiency on CKD. Single-cell transcriptomic analyses were performed on 47,885 cells from the renal cortex of both healthy and Rtn3-null mice, enabling us to compare spatial architectures and expression profiles across 14 distinct cell types. Our analysis revealed that RTN3 deficiency leads to significant alterations in the spatial organization and gene expression profiles of renal cells, reflecting CKD pathology. Specifically, RTN3 deficiency was associated with Lars2 overexpression, which in turn caused mitochondrial dysfunction and increased reactive oxygen species levels. This shift induced a transition in renal epithelial cells from a functional state to a fibrogenic state, thus promoting renal fibrosis. Additionally, RTN3 deficiency was found to drive the endothelial-to-mesenchymal transition process and disrupt cell-cell communication, further exacerbating renal fibrosis. Immunohistochemistry and Western-Blot techniques were used to validate these observations, reinforcing the critical role of RTN3 in CKD pathogenesis. The deficiency of RTN3 protein in CKD leads to profound changes in cellular architecture and molecular profiles. Our work seeks to elevate the understanding of RTN3's role in CKD's narrative and position it as a promising therapeutic contender.
Monitoring system configured to provide a health chart on an operator display. The health chart includes a plurality of indicators that identify patient parameters. The plurality of indicators form a column that extends parallel to a first axis. The health chart also includes linear projections that are aligned with respective indicators and extend parallel to a second axis that is perpendicular to the first axis. The linear projections represent values of the patient parameters that correspond to the respective indicators. The values are determined by the physiological data obtained from corresponding sensors. The patient monitoring system is configured to determine lengths of the linear projections based on the physiological data. The lengths extend from proximal ends of the linear projections to distal ends of the linear projections. The distal ends move parallel to the second axis toward or away from the respective indicators to change the length.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to traumatology and orthopedics, and can be used for rational perioperative management of patients with periprosthetic infection in the region of the hip joint when performing sanitation surgery with removal of the endoprosthesis and installation of the antimicrobial cement spacer. Method involves draining a postoperative wound and pharmacological prevention of venous thromboembolic complications by anticoagulants in doses indicated for orthopedic operations. Drainage is performed within one day after surgical intervention. That is followed by performing the puncture of the operated joint on 3rd and 7th days. First introduction of low-molecular heparin is performed not earlier than 12 hours after the operative intervention and then every 24 hours for 4 days. From 5-th day, direct oral anticoagulants are prescribed in standard doses of up to 35 days.EFFECT: method provides reliable and significant reduction of total and postoperative drainage blood loss, preserves high thromboprophylaxis, reduces the need for allogenic blood transfusion and prevents the local concentration of antibacterial agents in the postoperative wound by reducing the loss thereof with a drainage detachable.1 cl, 1 tbl, 1 ex
PURPOSE:To obtain a preventive and a therapeutic agent for bone resorption diseases such as hypercalcemia or osteoporosis, having inhibitory action on liberation of Ca and inorganic phosphorus, comprising an extract rich in polyphenols prepared from a rosaceous, theaceous or moraceous plant as an active ingredient. CONSTITUTION:Petals of at least one king of plant such as rosaceous plant (e.g. agrimony), theaceous plant (tea) or moraceous plant (e.g. mulberry) are finely cut, immersed in 50% aqueous solution of ethanol for three days and filtered. The residue is remixed with 50% aqueous solution of ethanol, immersed further for three days and filtered. The filtrate is collected, concentrated under reduced pressure, freeze-dried to give an extract rich in polyphenols. Then the extract is used as an active ingredient, combined with a well-known medical carrier and pharmaceutically manufactured to give a preventive and therapeutic agent for bone resorption diseases such as malignant hyper calcemia, Paget's disease of bone and osteoporosis having high safety. This extract is added to a food and a drink and can be used as a healthy food to be taken daily.
For patients not adequately controlled on glyburide and metformin hydrochloride tablets, a thiazolidinedione can be added to glyburide and metformin hydrochloride tablets therapy. When a thiazolidinedione is added to glyburide and metformin hydrochloride tablets therapy, the current dose of glyburide and metformin hydrochloride tablets can be continued and the thiazolidinedione initiated at its recommended starting dose. For patients needing additional glycemic control, the dose of the thiazolidinedione can be increased based on its recommended titration schedule. The increased glycemic control attainable with glyburide and metformin hydrochloride tablets plus a thiazolidinedione may increase the potential for hypoglycemia at any time of day. In patients who develop hypoglycemia when receiving glyburide and metformin hydrochloride tablets and a thiazolidinedione, consideration should be given to reducing the dose of the glyburide component of glyburide and metformin hydrochloride tablets. As clinically warranted, adjustment of the dosages of the other components of the antidiabetic regimen should also be considered.
A white powder for reconstitution. Polyethylene Glycol 3350 NF (Polyethylene Glycol 3350 Powder For Oral Solution) is a synthetic polyglycol having an average molecular weight of 3350. The actual molecular weight is not less than 90.0 percent and not greater than 110.0 percent of the nominal value. The chemical formula is HO(C2H4O)nH in which n represents the average number of oxyethylene groups. Below 55°C it is a free flowing white powder freely soluble in water. Polyethylene Glycol 3350 NF is an osmotic agent for the treatment of constipation.
Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. 

Prior to use, check that the vial adaptor cover is intact. Check the solution container for minute leaks by squeezing inner bag firmly. If leaks are found or if the vial adaptor cover is not intact, discard product as sterility may be impaired.
Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.